Max Healthcare launches CAR-T cell therapy in collaboration with ImmunoACT https://ift.tt/jabNp1i

Also known as a ‘living drug’, this therapy provides enduring benefits and is recommended for those not able to undergo a stem cell transplant or post-transplant relapse. Compared to conventional therapies, this requires a brief, single-infusion treatment, enhancing the quality of life for many patients with an average of two weeks of in-patient care.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/4myuZre